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Background: The pathophysiology of early brain injury following aneurysmal subarach-
noid hemorrhage (SAH) is still not completely understood.
Objective: Using brain perfusion CT (PCT) and cerebral microdialysis (CMD), we 
examined whether non-ischemic cerebral energy dysfunction may be a pathogenic 
determinant of EBI.
Methods: A total of 21 PCTs were performed (a median of 41 h from ictus onset) among 
a cohort of 18 comatose mechanically ventilated SAH patients (mean age 58  years, 
median admission WFNS score 4) who underwent CMD and brain tissue PO2 (PbtO2) 
monitoring. Cerebral energy dysfunction was defined as CMD episodes with lactate/
pyruvate ratio (LPR) >40 and/or lactate >4 mmol/L. PCT-derived global CBF was cat-
egorized as oligemic (CBF < 28 mL/100 g/min), normal (CBF 28–65 mL/100 g/min), or 
hyperemic (CBF 69–85 mL/100 g/min), and was matched to CMD/PbtO2 data.
results: Global CBF (57 ± 14 mL/100 g/min) and PbtO2 (25 ± 9 mm Hg) were within 
normal ranges. Episodes with cerebral energy dysfunction (n = 103 h of CMD samples, 
average duration 7.4 h) were frequent (66% of CMD samples) and were associated with 
normal or hyperemic CBF. CMD abnormalities were more pronounced in conditions of 
hyperemic vs. normal CBF (LPR 54 ± 12 vs. 42 ± 7, glycerol 157 ± 76 vs. 95 ± 41 µmol/L; 
both p < 0.01). Elevated brain LPR correlated with higher CBF (r = 0.47, p < 0.0001).
conclusion: Cerebral energy dysfunction is frequent at the early phase following 
poor-grade SAH and is associated with normal or hyperemic brain perfusion. Our data 
support the notion that mechanisms alternative to ischemia/hypoxia are implicated in the 
pathogenesis of early brain injury after SAH.
Keywords: cerebral microdialysis, subarachnoid hemorrhage, neuroenergetics, hyperemia, early brain injury
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inTrODUcTiOn
Increasing evidence suggests that early events occurring dur-
ing the first 72  h following ictus onset, before the occurrence 
of secondary delayed neurological deterioration, substantially 
contribute to the pathophysiology and outcome of aneurysmal 
subarachnoid hemorrhage (SAH). This so-called early brain 
injury phase includes multiple physiological derangements that 
exacerbates the primary cerebral insult and may eventually 
worsen patient prognosis (1–6). While research efforts have 
predominantly focused on cerebral hemodynamics and perfu-
sion, and the comprehension of mechanisms involved in brain 
ischemia, it is now increasingly recognized that a number of 
alternative “non-ischemic” mechanisms are implicated in the 
pathogenesis of early brain injury (7).
Energy dysfunction has emerged as one potential pathogenic 
determinant of cerebral damage following acute brain injury. 
Using a combination of intra-cerebral microdialysis (CMD)—to 
quantify regional brain metabolism—and neuroimaging tech-
niques, to assess brain perfusion and oxygenation, several studies 
have reported profound derangements in the regulation of neu-
roenergetics in the absence of ischemia at the early phase of acute 
brain injury (8–15). So far, however, cerebral energy dysfunction 
has mainly been described following neurotrauma (16–19). 
Whether cerebral energy dysfunction contributes to early brain 
injury following SAH has not been extensively studied; moreover, 
its exact nature and potential cerebral blood flow (CBF) correlates 
have not been precisely characterized.
The aim of this study in comatose SAH patients who under-
went advanced multimodal neuromonitoring was to examine the 
relationship of cerebral energy metabolism (using CMD) with 
brain oxygenation (using brain tissue PO2, PbtO2) and CBF. CBF 
was quantified using brain perfusion CT (PCT) performed at 
the early phase of SAH. We hypothesized that early brain injury 
following SAH leads to an increase in neurochemical markers of 
cerebral energy dysfunction [CMD lactate and lactate/pyruvate 
ratio (LPR)] and brain cell damage (CMD glycerol) despite the 
absence of cerebral ischemia/hypoxia.
MaTerials anD MeThODs
Patients
Subjects were part of a retrospective observational cohort of 
patients with SAH admitted to the Intensive Care Unit who 
underwent CMD/PbtO2 monitoring and brain PCT as part of 
standard care. Indication for intracranial monitoring was a post-
resuscitation Glasgow Coma Scale <9. Subjects were recruited 
over a 2-year period (March 2013–April 2015); only patients who 
had complete CMD/PbtO2 data and in whom brain PCT was 
performed within 96 h from SAH were included in the present 
study. A subset of the present cohort was also included in another 
clinical investigation that evaluated that value of CMD to detect 
delayed cerebral ischemia, submitted elsewhere. Approval for 
the study was obtained from our local Ethical Committee, and 
a waiver of consent was given due to the retrospective nature of 
the study.
cerebral Microdialysis Monitoring
Cerebral microdialysis consisted of a CMA 70 catheter (20 kDa 
cutoff, CMA Microdialysis AB®, Stockholm, Sweden; flow rate 
0.3 µL/min), inserted through a triple-lumen bolt into subcortical 
white matter generally in the non-dominant frontal lobe in an 
area situated between the anterior and the middle cerebral artery 
territories. CMD samples were collected hourly and analyzed 
immediately at the bedside with the ISCUS flex system (CMA 
Microdialysis AB®) for brain extracellular concentrations of 
lactate, pyruvate, glucose, glutamate, and glycerol. First hour of 
monitored data, artifacts, and values outside obvious physiologi-
cal ranges were manually excluded. In all patients, PbtO2 (Licox®, 
Integra Neurosciences, Plainsboro, NJ, USA) and intracranial 
pressure (ICP; Codman®, Raynham, MA, USA) probes were also 
inserted, adjacent to the CMD catheter. The correct placement of 
all probes was verified within 24 h by a follow-up non-contrast 
head CT scan.
general Patient Management
Patients were managed according to a written standardized 
algorithm, in line with international guidelines (20). After initial 
stabilization, the ruptured aneurysm was secured either by surgi-
cal clipping or by endovascular coiling. All patients were mechani-
cally ventilated, targeting a PaO2 of 90–100 mm Hg and a PaCO2 of 
35–40 mm Hg. Cerebral perfusion pressure (CPP) was maintained 
at least >70 mm Hg, if needed with the use of fluids (crystalloids) 
and vasopressors (norepinephrine). Blood glucose was maintained 
at 6–8 mmol/L, and enteral nutrition was started within 48 h.
Brain Perfusion computed Tomography
Neuroimaging was conducted in stable conditions of ICP, and 
systemic hemodynamics. PCT was performed using a multi-
detector row CT Lightspeed (GE medical systems, Milwaukee, 
WI, USA). Scanning was initiated 5  s after injection of 50  mL 
of iohexol (300 mg/mL of iodine; GE Healthcare Europe), per-
fused at a rate of 5 mL/s, with the following parameters: 80 kV, 
240 mAs, 0.4 rotations/s, and total duration of 50 s. The series 
evaluated 16 adjacent 5-mm-thick sections of brain parenchyma. 
Postprocessing of PCT data was performed by an experienced 
neuroradiologist, masked to CMD and PbtO2 variables, using 
a dedicated software (Brilliance Workspace Portal®, Philips 
Medical Systems, Cleveland, OH, USA), which uses the central 
volume principle using deconvolution to measure the mean 
transit time (MTT). Cerebral blood volume (CBV) is calculated 
from the time-enhancement curves, and CBF is derived from the 
equation: CBF = CBV/MTT.
We defined four main regions of interest (ROIs): right and left 
middle cerebral artery, right and left anterior cerebral artery. CBF 
from posterior and cerebellar arteries territories were not analyzed 
in this study. Three-dimensional reconstruction was processed 
with Carestream Vue PACS (Carestream Health, Rochester, NY, 
USA) using a series of the thin-slice enhanced brain CT. Because 
intracranial probes were located in the white matter, ROIs were 
drawn in areas of predominant white matter to allow concord-
ant measurement of global supratentorial perfusion in the same 
type of tissue. All procedures and the ROIs’ characteristics were 
TaBle 1 | Cerebral blood flow (CBF) during the early brain injury phase following 
aneurysmal subarachnoid hemorrhage.
region of interest cBF, ml/100 g/min
Right middle cerebral artery 59.6 (29.3–96.8)
Left middle cerebral artery 63.9 (29.4–87.7)
Right anterior cerebral artery 55.9 (28.1–97.8)
Left anterior cerebral artery 62.2 (26.5–83.7)
Global 59.7 (27.7–84.5)
CBF was calculated with brain perfusion CT (n = 21, performed a median of 41 h from 
ictus onset) in four different regions of interest (ROIs); global CBF was defined as the 
average of CBF from the four different ROIs.
Data are expressed as mean (range).
TaBle 2 | Global cerebral blood flow (CBF), main brain physiologic, and cerebral 
metabolic variables at the time of brain perfusion CT.
Variable Value
cerebral perfusion
CBF, mL/100 g/min 57 ± 14
cerebral hemodynamics
Brain tissue PO2, mm Hg 25 ± 9
Intracranial pressure, mm Hg 13 ± 7
Cerebral perfusion pressure, mm Hg 77 ± 9
cerebral metabolism
Brain extracellular lactate/pyruvate ratio 42 ± 16
Brain extracellular lactate, mmol/L 5.3 ± 3.3
Brain extracellular pyruvate, μmol/L 141 ± 99.2
Brain extracellular glycerol, μmol/L 121 ± 65
Brain extracellular glutamate, μmol/L 29 ± 39
Brain extracellular glucose, mmol/L 1.1 ± 0.7
Data are presented as mean ± SD. Brain extracellular concentrations were measured 
with cerebral microdialysis.
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selected in line with previous studies (16). Global CBF was 
defined as the average of 4 ROIs’ CBF. Once the postprocessing 
completed, each PCT was then categorized as ischemic (global 
CBF  <  28  mL/100  g/min), normal (global CBF 28–66  mL/ 
100 g/min), or hyperemic (global CBF > 66 mL/100 g/min) (21, 22).
Determination of episodes with cerebral 
energy Dysfunction
Episodes with cerebral energy dysfunction were defined by LPR 
>40 and/or lactate >4 mmol/L in brain extracellular fluid, accord-
ing to recent consensus guidelines (23). Simultaneous levels of 
CMD glutamate, glycerol, as well as PbtO2 and ICP (averaged to 
the hour previous to CMD sampling), were also collected. For the 
purpose of the study, we analyzed CMD data closest to the time 
of PCT data. Identification of episodes of energy dysfunction was 
conducted by LC and MO, blinded to PCT data.
statistical analysis
Variables of interest included cerebral metabolic (CMD derived) 
data, PbtO2, and PCT findings. Statistical analysis was performed 
using JMP-10® package software (SAS Institute, Cary, NC, USA). 
Results were expressed as mean ± SD or median and interquartile 
range, and comparisons between groups were explored using 
Student’s t-test or Mann–Whitney test as appropriate. Linear 
correlations were tested using the non-parametric Spearman’s 
correlation coefficient. Significance was set at a p < 0.05.
resUlTs
Patient characteristics
Out of a total of 29 patients who underwent CMD monitoring 
during the study period, complete dataset was available for 18 
non-consecutive comatose subjects who underwent 21 PCTs 
during the early post-injury phase [a median of 41 (25–73) h from 
ictus onset]. Patients were predominantly women (16/18), mean 
age was 58 ± 9 years, and modified Fisher scale was 3 (1 patient) 
or 4 (17 patients). All patients were sedated and mechanically 
ventilated at the time of CT perfusion.
Brain PcT during the early Brain injury 
Phase after sah
Brain PCT data are summarized in Table  1. No significant 
differences for CBF were found between the different vascular 
territories. Global CBF averaged 57 ± 14 mL/100 g/min: among 
the 21 PCTs, 14 showed normal CBF while 7 were classified as 
hyperemic. Importantly, among the three patients in whom brain 
PCT was performed twice, CBF findings were concordant over 
the two repeated measurements (i.e., two patients with normal 
CBF, and one patient with hyperemic CBF). When examining 
concomitant cerebral physiologic variables (n = 157 h of intrac-
ranial monitoring, Table 2), we found that ICP and PbtO2 were 
on average within normal ranges. In contrast, brain extracellular 
concentrations of LPR, glutamate and glycerol were all elevated 
(Table 2), indicating substantial cerebral metabolic abnormali-
ties in the early brain injury phase following SAH in our patient 
cohort, despite the absence of cerebral ischemia/hypoxia.
cerebral energy Dysfunction during the 
early Brain injury Phase following sah
The relationship of cerebral energy dysfunction (n =  103  h of 
CMD samples, average duration 7.4  h) with global CBF was 
further analyzed, according to CBF classification (normal vs. 
hyperemic). Figure  1 illustrates two representative patients in 
whom cerebral energy dysfunction was associated with normal 
(Figure 1A) or hyperemic (Figure 1B) CBF on PCT, and absence 
of low PbtO2.
Complete CMD data were available for 19 PCTs: episodes 
of cerebral energy dysfunction were observed in 14/19 PCT 
measurements, corresponding to 66% of total CMD samples 
examined. Nine PCTs showed normal CBF while five were hyper-
emic. Cerebral metabolic abnormalities were more pronounced 
in hyperemic than normal CBF (Table  3): cerebral hyperemia 
was associated with higher levels of brain extracellular LPR 
(54.1 ± 11.9 vs. 42.1 ± 6.5 when CBF was normal, p < 0.0001) 
and glycerol (157.0 ± 76.1 vs. 95.1 ± 41.4 µmol/L, p < 0.0001). 
Brain CMD glutamate also was higher when CBF was hyperemic 
(38.0 ±  51.5 vs. 25.9 ±  23.5  µmol/L when CBF was normal), 
although this did not reach statistical significance (p = 0.18). As 
shown in Table 3, ICP and PbtO2 did not differ between the two 
CBF conditions: only a minority of samples (16%) had elevated 
ICP >20 mm Hg or PbtO2 <15 mm Hg (11%).
TaBle 3 | Episodes of cerebral energy dysfunction categorized according to 
cerebral blood flow (CBF), dichotomized as normal vs. hyperemic.
normal  
cBF (n = 9)
hyperemic  
cBF (n = 5)
p-Value
CBF, mL/100 g/min 44.6 ± 13.3 69.9 ± 4.9 <0.0001
Brain lactate/pyruvate ratio 42 ± 7 54 ± 12 <0.0001
Brain glycerol, μmol/L 95.1 ± 41.4 157.0 ± 76.1 <0.0001
Brain glutamate, μmol/L 25.9 ± 23.5 38.0 ± 51.5 0.18
Brain tissue PO2, mm Hg 22.8 ± 12.2 26.2 ± 6.3 0.18
Intracranial pressure, mm Hg 14 ± 9 14 ± 6 0.75
FigUre 1 | Cerebral energy dysfunction is associated with normal or hyperemic CBF in the early brain injury phase of aneurysmal subarachnoid hemorrhage. 
Illustrative examples of two patients in whom cerebral energy dysfunction was associated with brain perfusion CT (PCT) showing normal (a) or hyperemic  
(B) CBF. Time from PCT to subarachnoid hemorrhage was 16 h in patient (a) and 38 h in patient (B). Brain extracellular concentrations of lactate/pyruvate (LP) ratio, 
glutamate, and glycerol were measured with a 20 kDa cerebral microdialysis catheter that was located in the subcortical white matter, adjacent to a brain tissue PO2 
(PbtO2) probe. Abbreviations: CBF, cerebral blood flow; CBV, cerebral blood volume; MTT, mean transit time.
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As shown in Figure 2, Spearman’s linear correlation coefficient 
analysis found a positive linear correlation of higher global CBF 
with both elevated brain LPR (r = 0.47, p < 0.0001) and brain 
glycerol (r = 0.58, p < 0.0001) during episodes of cerebral energy 
dysfunction, thereby suggesting that cerebral hyperemia cor-
related with more pronounced derangements in brain interstitial 
tissue biochemistry.
Global CBF was higher during episodes with cerebral energy 
dysfunction (n = 14; CBF 59.2 ± 15.7 mL/100 g/min) vs. those 
without (n = 5; CBF 51.2 ± 7.9 mL/100 g/min, p = 0.01).
FigUre 2 | Hyperemic cerebral blood flow (CBF) is positively correlated with cerebral metabolic and cellular distress. Graphs illustrate Spearman’s linear correlations 
of global CBF, measured with perfusion CT, with brain extracellular concentrations of lactate/pyruvate (LP) ratio and glycerol.
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DiscUssiOn
Our data combining regional brain tissue monitoring with 
perfusion head CT scan demonstrate that cerebral energy dys-
function may occur despite absence of brain hypoxia/ischemia, 
since PbtO2 was on average within normal ranges and cerebral 
perfusion was normal, or even supranormal. This clinical study 
identifies cerebral energy dysfunction as a novel pathogenic 
determinant of early brain injury following SAH. Our findings 
further suggest that, at the early phase of SAH, interventions 
targeted to cerebral perfusion and oxygenation may not be suf-
ficient to prevent further secondary brain damage. It is plausible 
to conceive that alternative strategies aimed at improving cerebral 
energy metabolism may be of value in this setting.
cerebral Perfusion in the early Brain  
injury Phase of sah
All PCTs were showing normal to supranormal CBF. Our find-
ings (see Table 1) are in line with previous clinical observations 
showing that CBF measured at the early acute phase following 
SAH was on average above 54 mL/100 g/min, irrespective of later 
occurrence of delayed cerebral ischemia (24, 25). Normal CBF 
was associated with normal PbtO2 and ICP values. Thus, our 
study combining cerebral perfusion imaging with monitoring 
of regional brain physiology did not reveal evidence of cerebral 
ischemia or hypoxia in our patient cohort, at least at the time 
interval where neuroimaging was performed.
cerebral energy Dysfunction in the early 
Phase following sah is non-ischemic
Despite assessment of cerebral perfusion, oxygenation and 
hemodynamics showed absence of abnormalities, sampling of 
patient brain extracellular fluid obtained at the time interval of 
PCT revealed levels of LPR, glutamate, and glycerol that were 
all pathologically elevated (see Table 2). These neurometabolic 
abnormalities were all clinically relevant: in particular, brain LPR 
was on average above 40, a threshold that is associated with worse 
neurological recovery (17, 23, 26).
When focusing on episodes of cerebral energy dysfunction, 
we found that these were frequent, corresponding to two thirds 
of total CMD samples collected during PCTs. We found that 
cerebral energy dysfunction was not associated with ischemia/
oligemia, but rather with normal to supranormal CBF. Previous 
clinical investigation in patients with traumatic brain injury 
revealed that energy dysfunction is predominantly non-ischemic 
(16, 17) and unrelated to reduced cerebral perfusion (27, 28). 
To the best of our knowledge, this is the first study to show 
evidence of non-ischemic/hypoxic cerebral energy dysfunction 
during the early brain injury phase following SAH in humans.
Interestingly, when dichotomizing global CBF data as normal 
vs. hyperemic (Table  3), hyperemia correlated with a greater 
impairment of cerebral energy metabolism and higher levels of 
cerebral glycerol, a marker of brain cell membrane disruption. 
Brain glutamate, a marker of brain excitotoxicity, was also higher 
in hyperemic conditions. In line with this, we observed that brain 
LPR and glycerol were positively correlated with increased CBF 
(Figure  2). Altogether, these findings establish a link between 
hyperemia and the severity of neurochemical derangements.
Potential Mechanisms Underlying 
cerebral energy Dysfunction
Our data support the notion that mechanisms alternative to 
ischemia or hypoxia may be implicated in the pathogenesis of 
cerebral energy dysfunction following SAH. Hyperglycolysis 
(10, 14, 15, 29, 30), mitochondrial dysfunction (31), electro-
graphic seizures (18), and cortical spreading depression (32) have 
been associated with cerebral energy dysfunction and metabolic 
crisis. Cerebral energy dysfunction is now well recognized as an 
6Carteron et al. Energy Dysfunction after SAH
Frontiers in Neurology | www.frontiersin.org July 2017 | Volume 8 | Article 325
important determinant of secondary brain injury (11) and patient 
prognosis (19, 33), at least in patients with traumatic brain injury.
The association between hyperemia and cerebral energy 
dysfunction during the early brain injury phase of SAH is 
not unprecedented and may help understanding underlying 
mechanisms. A growing body of evidence suggests that corti-
cal spreading depression might play an important role in the 
pathophysiology of secondary cerebral damage following acute 
brain injury in general and are implicated in the early brain 
injury phase following SAH (34). Sakowitz and colleagues indeed 
found a relationship between cortical spreading depression and 
cerebral energy dysfunction in patients with SAH (35). Persistent 
impairment of cerebral energy metabolism might occur despite 
apparent hyperemia (36). Further study is needed to examine the 
exact relationship of causality between spreading depressions and 
cerebral energy dysfunction following SAH: it is also conceiv-
able that treatment of spreading depressions may improve brain 
energetics.
Mitochondrial dysfunction is characterized by increased LPR, 
because of elevated brain lactate but with normal-to-elevated 
levels of pyruvate and PbtO2 (31). This cerebral metabolic pat-
tern is distinct from that seen in ischemia where LPR elevation 
is coupled with low pyruvate and PbtO2 (23). Here, episodes of 
cerebral energy dysfunction were associated with normal PbtO2 
and CBF, and also with normal-to-elevated brain extracellular 
pyruvate (on average 141.0 ± 99.2 µmol/L), thereby suggesting 
that mitochondrial dysfunction may be potentially implicated. 
Finally, elevated lactate may be secondary to increased activation 
of astrocytic glycolysis (29, 30).
Potential clinical implications
Diagnosis of cerebral energy dysfunction requires advanced brain 
monitoring with the use of the cerebral microdialysis technique, 
thereby reinforcing the utility of this monitoring modality for the 
care of patients with poor-grade SAH (37). The fact that cerebral 
energy dysfunction might occur despite brain physiology (ICP 
and PbtO2) and CBF are normal (or even supranormal) indicates 
that therapy targeted solely to improve cerebral oxygenation 
and perfusion may not be enough to mitigate brain damage 
during the acute phase following SAH. While ischemia/hypoxia 
undoubtedly might play a role in the pathogenesis of SAH, the 
scientific paradigm has increasingly turned its interest toward 
the search for alternative mechanisms (7), particularly at the 
early brain injury phase (1, 4). Emerging evidence suggests that 
therapies aimed at modulating neuroenergetics might be protec-
tive after brain injury (38). Recent clinical investigation further 
demonstrates that resuscitation of the injured human brain with 
hypertonic lactate solutions exerts a beneficial effect on cerebral 
energy metabolism (39, 40).
study limitations
The first limitation is related to the single-center observational 
cohort and the relatively small sample-size, which limits data 
generalizability. PCTs, however, were analyzed blinded to 
intracranial monitoring data; similarly, CMD and other brain 
physiological data were matched to PCTs in a blinded fashion. 
Although a correlation between CBF and CMD LPR and glycerol 
was found during episodes of cerebral energy dysfunction, due to 
the limited number of patients we could not use multiple regres-
sion with adjustment of cofactors, therefore we cannot confirm a 
causal relationship.
Timing of brain imaging is an important issue. Although 
brain PCT was performed at a relatively early phase after SAH 
(median 41 h from ictus onset) the role of initial global ischemia 
after SAH cannot be extrapolated from our data. Previous studies 
performed at the very early phase (<12 h) indeed reported acute 
cerebral hypoperfusion in subjects with SAH undergoing Xenon 
contrast-enhanced CT scanning (41). Our findings therefore 
apply more to the post-resuscitation ICU phase (approximately 
day 1–3).
Based on our local practice in patients with high grade SAH, 
CPP was kept >70 mm Hg (average CPP was 77 ± 9 mm Hg). 
As the major finding of this study was that cerebral energy 
dysfunction was frequent and was associated with normal to 
hyperemic CBF, it is unclear whether this was due only to the 
intrinsic SAH pathophysiology or whether this was, at least in 
part, caused or even exacerbated by elevated CPP. Based on these 
data, a preventive strategy of CPP augmentation may not seem 
justified in patients with SAH, since it may potentially aggravate 
cerebral energy dysfunction. Our data appear in line with previ-
ous microdialysis studies in patients with traumatic brain injury, 
showing that lower CPP (50–60  mm  Hg) may be sufficient to 
preserve normal cerebral energy metabolism (42).
PCTs were performed in stable conditions, after initial resus-
citation. This is an advantage in terms of the homogeneity of the 
data analyzed. However, our findings only apply to early post-SAH 
phase when ICP and CPP are stable, but we cannot extrapolate our 
findings to conditions of more disturbed intracranial physiology 
(e.g., intracranial hypertension). While matching of PCT with 
CMD and PbtO2 data offers a comprehensive view of the injured 
brain state, on the other hand it only provides a partial view of the 
overall picture. This is mainly because PCTs is not available con-
tinuously. Our study should therefore be considered as hypothesis 
generating, and further investigation is needed to confirm our 
findings. We believe, however, that, notwithstanding these limita-
tions, this clinical study identifies cerebral energy dysfunction as a 
novel pathogenic determinant of early brain injury following SAH.
cOnclUsiOn
Our study in patients with comatose aneurysmal SAH who under-
went advanced brain monitoring with cerebral microdialysis and 
PbtO2, in combination with PCT performed during the early phase 
following ictus onset, indicates that cerebral energy dysfunction 
is frequent and is associated with normal to hyperemic CBF. 
Our data identify an alternative pathogenic mechanism of early 
brain injury following SAH in humans, which appears unrelated 
to cerebral ischemia/hypoxia. Management targeted to improve 
energy substrate delivery—together with adequate cerebral per-
fusion and oxygenation—may help attenuating secondary brain 
damage at the early phase of SAH. Additional study is needed 
to characterize the exact mechanisms of SAH-related cerebral 
energy dysfunction and to examine whether timely diagnosis and 
treatment may translate into better patient outcome.
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